Generer rapport
Teitur Trophics Aps
Palle Juul-Jensens Boulevard 82, 8200 Aarhus N, CVR 41058439
Virksomhedsform
Anpartsselskab
Etableret
2020
Størrelse
Mikro
Ansatte
2
Omsætning
-
DKK
Bruttofortj.
-3.694.585
DKK
Primært resultat (EBIT)
-5.436.317
DKK
Årets resultat
-5.534.176
DKK
Egenkapital
-16.948.846
DKK
Reklamebeskyttet virksomhed
Denne virksomhed er reklamebeskyttet. Det betyder bl.a. at oplysningerne ikke må bruges til reklamehenvendelser. annonce
Flere nøgletal og analyser?
Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!
Rang Årets resultat
Rang i branche
125/160
"Bund 35%"
Rang i Danmark
336.350/343.294
"Bund 10%"
Direktion top 3
| Simon Mølgaard Jensen 4 | Direktør |
Bestyrelse top 3
| Charles Henry Large 1 | Bestyrelsesformand |
| Simon Mølgaard Jensen 4 | Bestyrelsesmedlem |
| Casper Breum 3 | Bestyrelsesmedlem |
Legale ejere top 3
| 15-19.99% | Innovestor Life Science Fund Ky | FI |
| 15-19.99% | Stiftelsen Industrifonden | SE |
| 15-19.99% | Sunstone Life Science Ventures Fund Iv K/S | DK |
Tegningsregler
Selskabet tegnes af en direktør og to bestyrelsesmedlemmer i forening, af tre bestyrelsesmedlemmer i forening, eller af den samlede bestyrelse.
Stamoplysninger baseret på CVR
| Navn | Teitur Trophics Aps |
| CVR | 41058439 |
| Adresse | Palle Juul-Jensens Boulevard 82, 8200 Aarhus N |
| Branche | Fremstilling af farmaceutiske præparater [212000] |
| Etableret | 08-01-2020 (4 år) |
| Første regnskabsperiode | 08-01-2020 til 31-12-2020 |
| Virksomhedsform | Anpartsselskab |
| Antal ansatte | 5 (årsværk:4) |
| Reklamebeskyttelse | Ja |
| Revisor | Ey Godkendt Revisionspartnerselskab siden 08-03-2023 |
| Regnskabsperiode | 01-01 til 31-12 |
| Selskabskapital | 154.130 DKK 93.819 DKK (08-03-2023 - 07-12-2023) 40.000 DKK (08-01-2020 - 07-03-2023) |
| Vedtægter seneste | 08-12-2023 |
Medlem af brancherne
- Fremstilling af farmaceutiske præparaterNACE6 indeholdende 205 virk.
- Fremstilling af farmaceutiske præparaterNACE3 indeholdende 205 virk.
- Fremstilling af farmaceutiske råvarer og farmaceutiske præparaterNACE2 indeholdende 243 virk.
- FremstillingsvirksomhedNACE1 indeholdende 26.274 virk.
Formål
Selskabets formål er at forske i, udvikle, producere og sælge bioteknologiske produkter og medicinalprodukter samt anden virksomhed, der efter ledelsens skøn er forbundet dermed.
Regnskab
| 2022 | 2021 | 2020 | |
|---|---|---|---|
| Valuta/enhed | 000' DKK | 000' DKK | 000' DKK |
| Omsætning | - - | - - | - - |
| Bruttofortjeneste | -3.695 - | -6.988 - | -2.396 - |
| Årets resultat | -5.534 - | -8.062 - | -3.392 - |
| Egenkapital | -16.949 - | -11.415 - | -3.352 - |
| Balance | 5.109 -44% | 9.075 +98% | 4.576 - |
Ledelsesberetning
Development in activities and financial and economic position
The company's income statement for the financial year 2022 shows a loss of 5,534 DKK ('000) and the company's balance sheet per 31 December 2022 shows an equity of -16,949 DKK ('000). The result is characterized by the fact that the company is in the start-up phase with limited operations and costs for research. The company's financial position complies with management's expectations and is considered satisfactory. The company has obtained external capital and liquidity, and it is management's expectation that this can cover the company's continued research and re-establish the company's share capital until research activities are completed, and future operation will be able to generate profit. Regarding to going concern, the company is therefore dependent on continued financing from lenders. However, redemption or conversion of the loan into shares can take place no earlier than the end of 2024. Tax receivables 952 DKK ('000) has been included as the company applies for payment under section 8 of the Tax Assessment Act - the tax credit scheme.
The company's income statement for the financial year 2022 shows a loss of 5,534 DKK ('000) and the company's balance sheet per 31 December 2022 shows an equity of -16,949 DKK ('000). The result is characterized by the fact that the company is in the start-up phase with limited operations and costs for research. The company's financial position complies with management's expectations and is considered satisfactory. The company has obtained external capital and liquidity, and it is management's expectation that this can cover the company's continued research and re-establish the company's share capital until research activities are completed, and future operation will be able to generate profit. Regarding to going concern, the company is therefore dependent on continued financing from lenders. However, redemption or conversion of the loan into shares can take place no earlier than the end of 2024. Tax receivables 952 DKK ('000) has been included as the company applies for payment under section 8 of the Tax Assessment Act - the tax credit scheme.
24-03-2023